



In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.

Item 8.01 Other Events.

On November 7, 2013, Array BioPharma issued a press release announcing that data will be presented on two drug candidates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor, at the 2013 Annual Meeting of the American Society of Hematology (ASH).

A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release announcing presentation of clinical data at the 2013 ASH Meeting on ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2013

Array BioPharma Inc.

By: /s/ R. Michael Carruthers
R. Michael Carruthers
Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release announcing presentation of clinical data at the 2013 ASH Meeting on ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor